BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 19187693)

  • 1. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
    Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
    Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of chemokines and chemokine receptors in HIV-1 infection.
    Murakami T; Yamamoto N
    Int J Hematol; 2000 Dec; 72(4):412-7. PubMed ID: 11197206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of chemokines in the HIV infection process].
    Proost P; Schols D
    Verh K Acad Geneeskd Belg; 2002; 64(6):403-20. PubMed ID: 12649932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
    Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
    J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pouncing on the chemokine receptor Chimera.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped.
    Doms RW
    Top HIV Med; 2004; 12(4):100-3. PubMed ID: 15516706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV type 1 tropism and inhibitors of viral entry: clinical implications.
    Weber J; Piontkivska H; Quiñones-Mateu ME
    AIDS Rev; 2006; 8(2):60-77. PubMed ID: 16848274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
    Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor.
    Calado M; Matoso P; Santos-Costa Q; Espirito-Santo M; Machado J; Rosado L; Antunes F; Mansinho K; Lopes MM; Maltez F; Santos-Ferreira MO; Azevedo-Pereira JM
    Virology; 2010 Dec; 408(2):174-82. PubMed ID: 20947116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology of HIV coreceptor tropism.
    Hoffmann C
    Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
    Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
    Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects of HIV-1 entry inhibitors as novel therapeutics.
    Pierson TC; Doms RW; Pöhlmann S
    Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
    Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.